Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 5/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 2/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10887507 | 0.84 | IDO1 (0.45) | IDO1AGXTMAOBAPPCCR5 | |
| SCHEMBL6236934 | 0.79 | IDO1 (0.53) | IDO1NPC1RAB9ATAAR1 | |
| SCHEMBL287942 | 0.78 | TSHR (0.48) | IDO1AGXTMAOBSLC6A2SLC6A3 | |
| SCHEMBL3352453 | 0.78 | IDO1 (0.52) | IDO1AGXTMAOBAPPCCR5 | |
| SCHEMBL5779495 | 0.78 | IDO1 (0.53) | IDO1AGXTMAOBAPPNPC1 | |
| SCHEMBL5778928 | 0.77 | CYP3A4 (0.55) | IDO1AGXTMAOBMAOATAAR1 | |
| SCHEMBL8817 | 0.74 | IDO1 (0.52) | IDO1AGXTMAOBAPPTACR2 | |
| SCHEMBL26313534 | 0.73 | IDO1 (0.47) | IDO1AGXTMAOBAPPCCR5 | |
| SCHEMBL2655920 | 0.71 | IDO1 (0.54) | IDO1AGXTMAOBAPPTACR2 | |
| SCHEMBL10793621 | 0.71 | KCNH2 (0.39) | IDO1AGXTTACR2KMT2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004089903-A9 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER LAMBERT CO (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | disclosed |
| US-4598155-A | 3(5-tetrazolyl)1,4-diaminoanthraquinones | CIBA-GEIGY CORPORATION (US) | 1986-07-01 | — | — | US | disclosed |
| EP-0079862-B1 | 1,4-DIAMINO-ANTHRAQUINONE COMPOUNDS | CIBA-GEIGY AG (CH) | 1986-01-15 | — | — | EP | disclosed |
| EP-0079862-A2 | 1,4-Diamino-anthraquinone compounds | CIBA-GEIGY AG (CH) | 1983-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | REN, ACE, HPN | IDO1 4079/4885AGXT 3314/4885MAOB 1068/4885 |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | IDO1 4197/4885AGXT 1962/4885MAOB 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.